Sucralfate versus histamine 2 receptor antagonists for stress ulcer prophylaxis in adult critically ill patients: A meta-analysis and trial sequential analysis of randomized trials


    loading  Checking for direct PDF access through Ovid

Abstract

PurposeTo determine the impact of using sucralfate versus H2RAs for SUP on patient important outcomes.Materials and methodsWe searched CENTRAL, MEDLINE, EMBASE, ACPJC, clinical trials registries, and conference proceedings through June 2016 for randomized controlled trials (RCTs) comparing sucralfate to H2RAs for SUP in adult critically ill patients.Results21 RCTs enrolling 3121 patients met inclusion criteria. There was no significant difference between sucralfate compared to H2RAs in the risk of clinically important GI bleeding (risk ratio [RR] 1.19; 95% CI [confidence interval] 0.79, 1.80; P = 0.42; I2 = 0%; low quality evidence). However, there was a statistically significant lower risk of ICU acquired pneumonia with sucralfate compared to H2RAs (RR 0.84; 95% CI 0.72, 0.98; P = 0.03; I2 = 0%; moderate quality evidence). Sucralfate did not significantly affect the risk of death (RR 0.95; 95% CI 0.82, 1.10; P = 0.51; I2 = 0%; high quality evidence), or duration of ICU stay in days (mean difference − 0.39; 95% CI [− 1.12, 0.34]; P = 0.29; I2 = 0%; moderate quality evidence). Trial sequential analysis adjusted estimates were consistent with conventional estimates.ConclusionModerate quality evidence suggests that sucralfate reduced ICU acquired pneumonia compared to H2RAs in adult critically ill patients, with no significant impact on GI bleeding or death.HighlightsSucralfate may reduce risk of nosocomial pneumonia in critically ill adults when compared to histamine 2 receptor antagonists.Sucralfate is a reasonable alternative for stress ulcer prophylaxis in institutions where pneumonia is common.No studies examined the effect of either interventions on risk of Clostridium difficile colitis

    loading  Loading Related Articles